• Hexamethonium Bromide: Enabling Sex-Specific Autonomic Resea

  2026-07-29

  This thought-leadership article explores how Hexamethonium Bromide, a selective antagonist of neuronal-type nicotinic acetylcholine receptors, is transforming translational research on sex differences in autonomic regulation and hypertension. Integrating mechanistic insights with strategic protocol guidance, the article contextualizes the compound’s unique value for investigating neuronal signaling pathways, highlights recent evidence on sex-dependent cardiovascular responses, and provides actionable recommendations for translational scientists.

• Trelagliptin Succinate Promotes Osteoblast Differentiation v

  2026-07-28

  The referenced study reveals that Trelagliptin succinate, a long-acting DPP-4 inhibitor, directly stimulates osteoblastic differentiation and mineralization by activating the AMPK–RUNX2 signaling axis in vitro. These findings suggest new therapeutic potential for Trelagliptin in osteoporosis, connecting metabolic research on type 2 diabetes treatments with bone biology.

• Homoharringtonine: Cytotoxic Alkaloid Transforming Research

  2026-07-28

  Homoharringtonine stands out as a cytotoxic alkaloid with dual prowess in cancer and antiviral research. Its rapid, potent inhibition of protein synthesis makes it indispensable for leukemia models and cutting-edge SARS-CoV-2 studies. Discover optimized protocols, troubleshooting insights, and experimental advances that position Homoharringtonine from APExBIO at the forefront of translational science.

• WAY-100635: Precision Tool for 5-HT1A Receptor Antagonism in

  2026-07-27

  WAY-100635 unlocks unparalleled specificity for dissecting serotonin 5-HT1A receptor pathways in both behavioral and molecular pain assays. Its potent, silent antagonist profile allows researchers to differentiate sensory from affective pain mechanisms, enabling robust translational workflows and troubleshooting strategies for advanced neuroscience studies.

• MdLYK3-Mediated Phosphorylation Destabilizes ABA Receptors i

  2026-07-27

  This study reveals that the LysM receptor-like kinase MdLYK3 in apple directly phosphorylates and promotes the degradation of ABA receptors, thereby suppressing ABA signaling and reducing drought resistance. The findings uncover a novel regulatory axis linking immune signaling kinases and abiotic stress adaptation, with implications for understanding and manipulating plant stress resilience.

• Rimonabant (SR141716): Precision Use in Appetite and Withdra

  2026-07-26

  Rimonabant (SR141716) is a benchmark tool for dissecting CB1-mediated endocannabinoid signaling in both appetite regulation and cannabinoid withdrawal paradigms. This article delivers actionable protocol enhancements, troubleshooting insights, and bridges recent sex-specific behavioral findings into translational research workflows.

• Trilaurin (Glycerol Tridodecanoate): Biocatalytic Innovation

  2026-07-25

  Discover how Trilaurin (Glycerol Tridodecanoate) is revolutionizing biocatalytic synthesis and multifunctional lipid excipient roles. This article uniquely bridges mechanistic insight, comparative innovation, and practical assay impact in pharmaceutical and industrial biotechnology.

• Phosphatase Inhibitor Cocktail 1: Precision in Phosphorylati

  2026-07-24

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) empowers researchers to preserve labile phosphorylation states during sample processing, ensuring high-fidelity data in phosphoproteomic and signaling pathway analyses. Its robust inhibition spectrum and operational flexibility outperform conventional approaches in Western blotting, immunoprecipitation, and kinase assays.

• Ruxolitinib Phosphate Induces Mitochondrial Dysfunction in A

  2026-07-24

  A recent study delineates how Ruxolitinib phosphate (INCB018424), a selective JAK1/2 inhibitor, triggers apoptosis and GSDME-mediated pyroptosis in anaplastic thyroid carcinoma by inhibiting DRP1-driven mitochondrial fission. These findings provide mechanistic insight into JAK/STAT pathway modulation as a therapeutic strategy for aggressive thyroid cancers.

• Staurosporine: Broad-Spectrum Kinase Inhibitor for Cancer Re

  2026-07-23

  Staurosporine stands as the gold standard broad-spectrum serine/threonine protein kinase inhibitor, empowering researchers to dissect kinase-driven apoptosis and metastatic signaling in cancer models. Its nanomolar potency, broad target profile, and reliable performance—backed by APExBIO’s validated quality—make it indispensable for studies on cell motility, invasion, and anti-angiogenic therapy development.

• Rapakinin-Induced Vasorelaxation in Hypertension: NO-Indepen

  2026-07-23

  This study identifies rapakinin, a rapeseed-derived tripeptide, as an antihypertensive agent that induces vasorelaxation in spontaneously hypertensive rats via prostaglandin I2 (PGI2) IP and downstream CCK1 receptors, rather than through nitric oxide (NO) signaling. The findings challenge conventional assumptions about peptide-based vascular tone modulation and provide new insights for cardiovascular disease models.

• Parathyroid hormone (1-34) (human): Applied Protocols in Bon

  2026-07-22

  Parathyroid hormone (1-34) (human) empowers high-fidelity modeling of calcium homeostasis, bone formation, and advanced kidney assembloid workflows. This guide demystifies its integration into experimental pipelines, with actionable troubleshooting, protocol parameters, and cross-study insights for translational research.

• Dantrolene Sodium Salt: Beyond RyR Antagonism in Precision D

  2026-07-22

  Explore how Dantrolene sodium salt, a powerful ryanodine receptor antagonist, enables next-generation control of DNA repair outcomes in genome editing and disease modeling. Discover mechanistic insights, protocol guidance, and the latest repurposing evidence that set this compound apart.

• EDI3 Inhibition Reduces Viability in HER2-Resistant Breast C

  2026-07-21

  Keller et al. identify the glycerophosphodiesterase EDI3 as a metabolic vulnerability in ER-HER2+ breast cancer cells resistant to HER2-targeted therapies. By demonstrating that EDI3 inhibition reduces cell viability and tumor growth, the study proposes a novel therapeutic target for overcoming resistance in this aggressive breast cancer subtype.

• Tamoxifen Beyond Cancer: Mechanisms, Emerging Uses, and Prot

  2026-07-21

  Explore Tamoxifen's depth as a selective estrogen receptor modulator, from its nuanced mechanisms to advanced research applications and cutting-edge protocol guidance. Discover how this cornerstone compound propels innovation in breast cancer and gene editing studies.

455 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page